News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

Engage Bio Acquired by Lilly to Support Development of Non-Viral Genetic Medicines

Thursday, May 21, 2026

Engage Biologics Inc a preclinical biotechnology company focused on nonviral DNA delivery has been acquired by Eli Lilly and Company

Hansa Biopharma signs €115 million IDEFIRIX licensing agreement with SERB Pharmaceuticals

Wednesday, May 20, 2026

Hansa Biopharma has entered into an exclusive licensing agreement worth million with SERB Pharmaceuticals for the development and commercialisation of IDEFIRIX imlifidase across Europe and the Middle East and North Africa MENA region

Regeneron and Parabilis Medicines Partner to Develop Novel Antibody-Helicon Therapies

Tuesday, May 19, 2026

Regeneron Pharmaceuticals has entered into a strategic research collaboration with Parabilis Medicines to develop multiple therapeutic candidates based on Parabilis Helicon peptide platform with a focus on AntibodyHelicon Conjugates AHCs

INmune Bio receives FDA Fast Track designation for XPro1595 in early Alzheimer’s disease

Friday, May 15, 2026

INmune Bio Inc has announced that the US Food and Drug Administration has granted Fast Track designation to XPro pegipanermin for the treatment of early Alzheimers disease

U.S. FDA Approves INQOVI® Plus Venetoclax for Acute Myeloid Leukaemia

Thursday, May 14, 2026

Taiho Oncology and Taiho Pharmaceutical have received approval from the US Food and Drug Administration for INQOVI decitabine and cedazuridine in combination with venetoclax for the treatment

Delos Capital and AP Biosciences partner to launch biotech companies for next-generation antibody development

Tuesday, May 12, 2026

Delos Capital and AP Biosciences Inc have announced a strategic collaboration to establish and incubate new biotechnology companies focused on developing nextgeneration antibody therapies

Sironax receives FDA Fast Track status for SIR2501 in chemotherapy-induced peripheral neuropathy

Tuesday, May 12, 2026

Sironax has received Fast Track designation from the US Food and Drug Administration FDA for its SARM inhibitor SIR for the treatment of chemotherapyinduced peripheral neuropathy CIPN

Actuate Therapeutics receives FDA IND clearance for oral elraglusib programme

Tuesday, May 12, 2026

Actuate Therapeutics Inc has received Investigational New Drug IND clearance from the US Food and Drug Administration FDA for a Phase study of the oral formulation of elraglusib

4basebio launches enzymatic ssDNA platform for gene editing applications

Tuesday, May 12, 2026

basebio PLC has launched a highcapacity singlestranded DNA ssDNA platform designed to support the development of gene editing and nucleic acidbased therapies

Rznomics Secures FDA RMAT Designation for Liver Cancer Candidate RZ-001

Monday, May 11, 2026

Rznomics has received Regenerative Medicine Advanced Therapy RMAT designation from the US Food and Drug Administration for RZ its investigational therapy for hepatocellular carcinoma HCC